Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study

https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde https://www.has-sante.fr/upload/docs/application/pdf/2021-03/actualisation_des_facteurs_de_risque_de_formes_graves_de_la_covid-19_et_des_reco_sur_la_strategie_de_priorisation_des_popula.pdf https://www.has-sante.fr/upload/docs/application/pdf/2021-02/strategie_de_vaccination_contre_le_sars-cov-2___vaccination_des_personnes_ayant_un_antecedent_de_covid-19_-_synthese.pdf Polack, 2020, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N Engl J Med., 31, 2603, 10.1056/NEJMoa2034577 Baden, 2021, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N Engl J Med., 4, 403, 10.1056/NEJMoa2035389 https://www.fda.gov/media/73679/download https://ansm.sante.fr/uploads/2021/03/19/20210319-covid-19-vaccins-pfizer-comirnaty-9.pdf Krammer, 2021, Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine, N Engl J Med., 10.1056/NEJMc2101667 Manisty, 2021, Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals, Lancet, 20, 1057, 10.1016/S0140-6736(21)00501-8 Abu Jabal, 2021, Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021, Euro Surveill., 26, 2100096, 10.2807/1560-7917.ES.2021.26.6.2100096 Prendecki, 2021, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine, Lancet, 27, 1178, 10.1016/S0140-6736(21)00502-X Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD; Com-COV Study Group.Shaw RH, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021 12:S0140-6736:01115-6.